Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Prostate Adenocarcinoma, Localized Prostate Carcinoma
Interventions: High Dose Rate Monotherapy; Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Abdominal Aortic Aneurysms
Interventions: Open surgical repair, Stent Graft; Procedure · Device
Lead sponsor: Lombard Medical; Industry
Eligibility: 21 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2020
U.S. locations: 38
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 35 more

Conditions: Lymphoma
Interventions: cyclophosphamide, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: Up to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Respiratory Viral Infection
Interventions: No Intervention; Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Palo Alto, California • Detroit, Michigan • Seattle, Washington

Conditions: COVID-19
Interventions: Hydroxychloroquine; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography, Fludarabine, Granulocyte Colony-Stimulating Factor, Idarubicin, Multigated Acquisition Scan, Pivekimab Sunirine; Procedure · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Interventions: Biospecimen Collection, Efineptakin alfa, Pembrolizumab, Biopsy; Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: cytarabine, idarubicin, dasatinib, laboratory biomarker analysis; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Duarte, California

Conditions: Postpartum, Women, Community Health Workers, Knowledge, High-risk, Self Efficacy, Intention, Attitude
Interventions: MOMS Postpartum Course; Other
Lead sponsor: KDH Research & Communication; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Interventions: Intismeran autogene, BCG; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 20
States / cities: Bakersfield, California • Los Alamitos, California • Los Angeles, California + 15 more

Conditions: High Blood Pressure
Interventions: MyBP, Personal BP monitor; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 55 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Parkinson's Disease
Interventions: Respiratory muscle strength training; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 45 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hyperlipidemia
Interventions: Placebo, MBX-8025, Atorvastatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 24 more

Conditions: Endometrial Cancer
Interventions: Carboplatin and Paclitaxel, Radiation Therapy; Drug · Radiation
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Marywood, Illinois

Conditions: Colorectal Cancer, Regorafenib, High Risk Patients
Interventions: Regorafenib (CT), Lorigerlimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain and Central Nervous System Tumors, Cerebral Edema
Interventions: Boswellia serrata extract, cyanocobalamin; Drug · Dietary Supplement
Lead sponsor: Ali Altunkaya; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pancreatic Adenocarcinoma
Interventions: ExAblate 2100; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hematopoietic Stem Cell Transplantation, Delirium, Thiamine Deficiency
Interventions: Thiamine, Normal saline; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: High Risk Pregnancy, Congenital Heart Disease, Fetal Hydrops, Twin Monochorionic Monoamniotic Placenta, Gastroschisis, Fetal Demise, Stillbirth, Fetal Arrhythmia, Long QT Syndrome, Intrauterine Fetal Death, Sudden Infant Death, Pregnancy Loss, Twin Twin Transfusion Syndrome, Birth Defect, Fetal Cardiac Anomaly, Fetal Cardiac Disorder, Fetal Death, Brugada Syndrome, Fetal Tachycardia
Interventions: Fetal Magnetocardiogram and Neonatal Electrocardiogram, Substudy only: Maternal/Infant Pharmacogenomic assessment postnatally; Diagnostic Test · Genetic
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Clinical High Risk Syndrome for Psychosis
Interventions: PRIME care, Usual care; Other
Lead sponsor: Yale University; Other
Eligibility: 12 Years to 30 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Frailty
Interventions: High Intensity Walking, Casual Speed Walking; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 60 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
Interventions: Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate, Recombinant Interferon Alfa-2b; Biological · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 493
States / cities: Mobile, Alabama • Fairbanks, Alaska • Fort Smith, Arkansas + 321 more

Conditions: Melanoma (Skin)
Interventions: interferon alfa-2b, observation; Biological · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2026
U.S. locations: 511
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 354 more

Conditions: Breast Cancer
Interventions: Stereo Navigator Accessory to PEM Flex PET Scanner; Device
Lead sponsor: Naviscan PET Systems; Industry
Eligibility: 25 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Boca Raton, Florida • Timonium, Maryland • Portland, Oregon + 2 more

Search by objective public record fields.

Two-fraction HDR Monotherapy for Localized Prostate Cancer

Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft

Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

A Study to Investigate Acute Respiratory Virus Infections in Participants at High Risk for Severe Illness

Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia

Monitoring and Outreach for Maternal Safety Postpartum

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

High BP and Home Monitoring Experience (HoME) Study

Masked Faces in Parkinson Disease: Mechanism and Treatment

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme

Magnetic Resonance Guided High Intensity Focused Ultrasound in Advanced Pancreatic Adenocarcinoma Treatment

High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation

Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise

PRIME vs Usual Care for Clinical High Risk

High Intensity Walking to Reduce Frailty

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Pilot Study to Evaluate High Resolution PET Image-Guidance for Sampling of Breast Abnormalities